Millipore Corp., Q1 2009 Earnings Call Transcript

Question-and-Answer Session

Operator

(Operator Instructions). Your first question comes from the line of Jon Wood with Banc of America.

Jon Wood - Banc of America

Hey, good afternoon.

Martin Madaus

Hi John.

Jon Wood - Banc of America

So Martin, on the Bioprocess business did you see any material contribution from new product, capacity builds or new indication builds or was the rebound primarily a function just the resumption of normal purchasing patterns.

Martin Madaus

I think predominantly there is the resumption of normal volumes that has the biggest impact. I know there are a few molecules that we are ramping up. I really don't know whether they individually made a big impact. But we know there are few molecules that just got approved. So just probably little bit of that in there.

Jon Wood - Banc of America

Okay. And then on the broader side has the instrumentation there been impacted at all by the capital spending related weakness.

Martin Madaus

Well it depends on the end market, we see continued strong growth on academic markets but we see the pharmaceutical markets have pulled back a bit.

Jon Wood - Banc of America

Okay. And Lab Water instrumentation did it actually grow on a constant currency basis?

Martin Madaus

We don’t break that out.

Jon Wood - Banc of America

Okay. And then Charlie could you give us whatever impact the FX had on the margin profile.

Charlie Wagner

John we don’t break it down that carefully for this purpose. So what I can tell you is, it was $0.09 on EPS.

Jon Wood - Banc of America

Negative?

Charlie Wagner

Negative.

Jon Wood - Banc of America

Okay, alright. Thank a lot.

Operator

Thank you your next question comes from the line of Ross Muken with Deutsche Bank.

Ross Muken - Deutsche Bank

Good afternoon and congratulations on a strong quarter.

Martin Madaus

Thanks.

Ross Muken - Deutsche Bank

There was a lot of noise made in the Biotech channel this quarter about inventory destocking and you heard some different commentary from some of the large players about, script performance. As you sort of look out, I mean, I know we obviously saw a nice stabilization in the comp in the following quarters pretty easy. But I think any clarity or any changes or any sort of actions you would have seen would be helpful or review of any thoughts on some of the things they have been discussed publicly, by some of the large peers.